Cholecystokinin antagonists: Pharmacological and therapeutic potential

Medicinal Research Reviews

Volumn 23, Issue 5, 2003, Pages 559-605

  Herranz, Rosario ^a  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

Author keywords

Antagonists; CCK1 receptors; CCK2 receptors; Colecystokinin

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; 4 [[5 (8 AZASPIRO[4.5]DECAN 8 YL) 4 [(3,5 DICHLOROBENZOYL)AMINO] 5 OXOPENTANOYL]AMINO] 5 (1 NAPHTHYLAMINO) 5 OXOPENTANOIC ACID; A 64718; ARGINIUM 4 [N (3 METHOXYPROPYL) N PENTYLCARBAMOYL] 5 (2 NAPHTHYLSULFONYL)PENTANOATE; ASPERLICIN; BENZODIAZEPINE DERIVATIVE; BENZOTRIPT; CHOLECYSTOKININ; CHOLECYSTOKININ OCTAPEPTIDE; CHOLECYSTOKININ RECEPTOR; CHOLECYSTOKININ RECEPTOR 1; CHOLECYSTOKININ RECEPTOR 2; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CHOLECYSTOKININ RECEPTOR STIMULATING AGENT; CR 2345; CR 2767; DEXLOXIGLUMIDE; G PROTEIN COUPLED RECEPTOR; GASTROINTESTINAL AGENT; LORGLUMIDE; LOXIGLUMIDE; N (3 QUINOLYLCARBONYL) DEXTRO GLUTAMIC ACID ALPHA DIPENTYLAMIDE; NEUROTRANSMITTER; PANCREAS ENZYME; PROGLUMIDE; PROKINETIC AGENT; QUINAZOLINONE DERIVATIVE; RECEPTOR SUBTYPE; SPIROGLUMIDE; TETRAGASTRIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANXIETY DISORDER; CARBOXY TERMINAL SEQUENCE; CHEMICAL STRUCTURE; ENTEROPATHY; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRACT; LEARNING; MEMORY; NERVOUS SYSTEM; NOCICEPTION; PANCREAS DISEASE; PANCREAS SECRETION; PROTEIN STRUCTURE; REVIEW; SATIETY; STOMACH ACID SECRETION; STOMACH EMPTYING; STOMACH PARESIS;

AMINO ACID SEQUENCE; ANIMALS; CENTRAL NERVOUS SYSTEM; CHOLECYSTOKININ; GASTRIC ACID; HUMANS; LIGANDS; MODELS, CHEMICAL; MOLECULAR SEQUENCE DATA; NEUROPEPTIDES; PEPTIDES; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, CHOLECYSTOKININ; TETRAGASTRIN;

EID: 0041919640     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.10042     Document Type: Review

References (282)

1. Ivy AC, Oldberg E. A Hormone mechanism for gall bladder contraction an evacuation. Am J Physiol 1928;86:599-613.
2. Jorpes E, Mutt V. Cholecystokinin and pancreozymin, one single hormone? Acta Physiol Scand 1966;66:196-202.
3. Mutt V, Jorpes JE. Structure of porcine cholecystokinin-pancreozymin. 1. Cleavage with thrombin and with trypsin. Eur J Biochem 1968;6:156-162.
4. Vanderhaeghen JJ, Signeau JC, Gepts W. New peptide in vertebrate CNS reacting with antigastrin antibodies. Nature 1975;267:604-605.
5. Beinfeld MC, Meyer DK, Eskay RL, Jensen JT, Brwnstein MJ. The distribution of cholecystokinin-immunoreactivity in the central nervous system of the rat, as determined by radioimmunoassay. Brain Res 1981;212:51-57.
6. Beinfeld MC, Palkovits M. Distribution of cholecystokinin (CCK) in the rat lower brain stem nuclei. Brain Res 1982;238:260-265.
7. Hökfelt T, Skirboll L, Everitt B, Meister B, Brownstein M, Jacobs T, Faden A, Kuga S, Goldstein M, Markstein R, Dockray G, Rehfeld J. Distribution of cholecystokinin-like immunoreactivity in the nervous system: Co-existence with classical neurotransmitters and other neuropeptides. Ann Ny Acad Sci 1985;448:255-274.
8. Crawley JN, Corwin RL. Biological actions of cholecystokinin. Peptides 1994;15:731-755.
9. Daugé V, Léna I. CCK in anxiety and cognitive processes. Neurosci Biobehav R 1998;22:815-825.
10. Griebel G. Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? Pharmacol Ther 1999;82:1-61.
11. Rehfeld J F. Cholecystokinin and panic disorder-three unsettled questions. Regul Peptides 2000;93:79-83.
12. Ritter RC, Covasa M, Matson CA. Cholecystokinin: Proofs and prospects for involvement in control of food intake and body weight. Neuropeptides 1999;33:387-399.
13. Moran TH. Cholecystokinin and satiety: Current perspectives. Nutrition 2000;16:858-865.
14. Degen L, Matzinger D, Drewe J, Beglinger C. The effect of cholecystokinin in controlling appetite and food intake in humans. Peptides 2001;22:1265-1269.
15. Wiesenfeld-Hallin Z, Xu X-J. The role of cholecystokinin in nociception, neuropathic pain and opiate tolerance. Regul Peptides 1996;65:23-28.
16. Szelényi Z. Cholecystokinin and thermoregulation - A minireview. Peptides 2001;22:1245-1250.
17. Itoh S, Lai H. Influences of cholecystokinin and analogues on memory processes. Drug Dev Res 1990;21:257-276.
18. Noble F, Roques BP. CCK-B Receptor: Chemistry, molecular biology, biochemistry and pharmacology. Prog Neurobiol 1999;58:349-379.
19. Ghijsen WEJM, Leenders AGM, Wiegant VM. Regulation of cholecystokinin release from central nerve terminals. Peptides 2001;22:1213-1221.
20. Crawley J N. Cholecystokinin-dopamine interactions. Trends Pharmacol Sci 1991;12:232-236.
21. Tanganelli S, Fuxe K, Antonelli T, O'Connor WT, Ferraro L. Cholecystokinin/dopamine/GABA interactions in the nucleus accumbens: Biochemical and functional correlates. Peptides 2001;22:1229-1234.
22. Shlik J, Vasar E, Bradwejn J. Cholecystokinin and psychiatric disorders. CNS Drugs 1997;8:134-152.
23. Noble F, Wank SA, Crawley JN, Bradwejn J, Seroogy KB, Hamon M, Roques BP. International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors. Pharmacol Rev 1999;51:745-781.
24. Crespi F, Corsi M, Reggiani A, Ratti E, Gaviraghi G. Involvement of cholecystokinin within craving for cocaine: Role of cholecystokinin receptor ligands. Exp Opin Invest Drugs 2000;9:2249-2258.
25. Deschenes RJ, Lorenz LJ, Haun RS, Roos BA, Collier KJ, Dixon JE. Cloning and sequence analysis of cDNA encoding rat preprocholecystokinin. Proc Natl Acad Sci USA 1984;81:726-730.
26. Martinez J. Gastrointestinal regulatory peptide receptors. In Hansch C, Sammes PG, Taylor JB, editors. Comprehensive Medicinal Chemistry. Vol 3, Emmett JC, editor. Oxford: Pergamon Press; 1990. p 926-959.
27. Wank SA. Cholecystokinin receptors. Am J Physiol 1995;269:G628-G646.
28. Vanhoutte PM, Humprey PPA, Spedding M. XI. International Union of Pharmacology. Recommendations for nomenclature of new receptor subtypes. Pharmacol Rev 1996;48:1-2.
29. Wank SA. G Protein-coupled receptors in gastrointestinal physiology I. CCK receptors: An exemplary family. Am J Physiol 1998;274:G607-G613.
30. Baber NS, Dourish CT, Hill DR. The role of CCK, caerulein and CCK antagonists in nociception. Pain 1989;39:307-328.
31. Feliciano LF, Mazzini BK, Cacheiro RGR, Cruz TN, Flórido JC, Nasello AG. Stimulation of either cholecystokinin receptor subtype reduces while antagonists potentiate or sensitize a morphine-induced excitatory response. Peptides 2001;22:1299-1304.
32. Logsdon CD. Glucocorticoids increase cholecystokinin receptors and amylase secretion in pancreatic acinar AR42J cells. J Biol Chem 1986;261:2096-2101.
33. Klueppelberg UG, Molero X, Barrett RW, Miller LJ. Biochemical characterization of the cholecystokinin receptor on CHP212 human neuroblastoma cells. Mol Pharmacol 1990;38:159-163.
34. Wank SA, Harkins RT, Jensen RT, Shapira H, de Weerth A, Slattery T. Purification, molecular cloning, and functional expression of the cholecystokinin receptor from rat pancreas. Proc Natl Acad Sci USA 1992;89:3125-3129.
35. de Weerth A, Pisegna JR, Wank S. Guinea pig gall bladder and pancreas possess identical CCK-A receptor subtypes: Receptor cloning and expression. Am J Physiol 1993;265: G1116-G1121.
36. de Weerth A, Pisegna JR, Huppi IK, Wank S. Molecular cloning, functional expression and chromosomal localization of the human cholecystokinin type A receptor. Biochem Biophys Res Commun 1993;194:811-818.
37. Ulrich CD, Ferber I, Holicky E, Hadac E, Buell G, Miller LJ. Molecular cloning and functional expression of the human gall bladder cholecystokinin A receptor. Biochem Biophys Res Commun 1993;193:204-211.
38. Reuben M, Rising L, Prinz C, Hersey S, Sachs G. Cloning and expression of the rabbit gastric CCK-A receptor. Biochim Biophys Acta 1994;1219:321-327.
39. Tatsuura G, Shinohara S, Shintaku H, Eigyo M, Matsushita A. Protective effect of CCK-8 and ceruletide on glutamate-induced neuronal cell death in rat neuron cultures: Possible involvement of CCK-B receptors. Neurosci Lett 1991;132:159-162.
40. Yasui M, Kawasaki K. CCK-B receptor activation protect CAI neurons from ischemia-induced disfunction in stroke-prone spontaneously hypertensive rats hippocampal slices. Neurosci Lett 1995;191:99-102.
41. Eigyo M, Katsuura G, Shintaku H, Shionohara S, Shiomi T, Matsushita A. Systemic administration of a cholecystokinin analogue, ceruletide protects against ischemia-induced neurodegeneration in gerbils. Eur J Pharmacol 1992;214:149-158.
42. Sacerdote P, Wiedermann CJ, Wahl LM, Pert CB, Ruff MR. Visualization of cholecystokinin receptors on a subset of human monocytes and in rat spleen. Peptides 1991;12:167-176.
43. Lignon MF, Bernad N, Martinez J. Pharmacological characterization of type B cholecystokinin binding sites on the human JURKAT T lymphocyte cell line. Mol Pharmacol 1991;39:615-620.
44. Rozengurt E, Walsh JH. Gastrin CCK, signaling, and cancer. Annu Rev Physiol 2001;63:49-76.
45. Wank SA, Pisegna JR, de Weerth A. Brain and gastrointestinal cholecystokinin receptor family: Structure and functional expression. Proc Natl Acad Sci USA 1992;89:8691-8695.
46. Menozzi D, Gardner JD, Maton PN. Properties of receptors for gastrin and CCK on gastric smooth muscle cells. Am J Physiol 1989;257:G73-G79.
47. Pisegna JR, d Werrth A, Wank SA. Molecular cloning of the human brain and gastric cholecystokinin receptor: Structure, functional expression and chromosomal localization. Biochem Biocphys Res Commun 1992;189:296-303.
48. Kopin AS, Lee Y-M, McBride EW, Miller LJ, Lu M, Lin HY, Kolakowski LF, Beinborn M. Expression cloning and characterization of the canine parietal cell gastrin receptor. Proc Natl Acad Sci USA 1992;89:3605-3609.
49. de Weerth A, von Schrenck T, Gronewold M, Freudenberg F, Mirau S, Schulz M, Greten H. Characterization of CCK receptors in stomach smooth muscle: Evidence for two subtypes. Biochim Biophys Acta 1997;1327:213-221.
50. Baldwin GS. Gastrin receptor structure. In: Walsh JH, editor. Gastrin. New York: Raven; 1993. p195-207.
51. Bold RJ, Ishizuka J, Townsend C M, Thompson JC. Gastrin stimulates growth of human colon cancer cells via a receptor other than CCK-A or CCK-B. Biochim Biophys Res Commun 1994;202:1222-1226.
52. Ishizuka J, Townsend CM, Bold RJ, Martinez J, Rodriguez M, Thompson JC. Effects of gastrin on 3′,5′-cyclic adenosine monophosfate, intracellular calcium, and phosphatidylinositol hydrolysis in human colon cancer cells. Cancer Res 1994;54:2129-2135.
53. Baldwin GS. Antiproliferative gastrin/cholecystokinin receptor antagonists target the 78-kDa gastrin-binding protein. Proc Natl Acad Sci USA 1994;91:7593-7597.
54. Seva C, Dickinson CJ, Yamada T. Growth-promoting effects of glycine-extended progastrin. Science 1994;265:410-412.
55. Alexander SPH, Mathie A, Peters AJ, editors. Cholecystokinin and gastrin receptors. Trends Pharmacol Sci, 2001 Nomenclature Supplement 2001;22:36-37.
56. Kopin AS, McBride EW, Quinn SM, Kolakowski LF, Beinborn M. The role of the cholecystokinin-B/gastrin receptor transmembrane domains in determining affinity for subtype-selective ligands. J Biol Chem 1995;270:5019-5023.
57. Silvente-Poirot S, Wank SA. A segment of five amino acids in the second extracellular loop of the cholecystokinin-B receptor is essential for selectivity of the peptide agonist gastrin. J Biol Chem 1996;271:14698-14706.
58. Silvente-Poirot S, Escrieut C, Wank SA. Role of the extracellular domains of the cholecystokinin receptor in agonist binding. Mol Pharmacol 1998;54:364-371.
59. Beinborn M, Lee Y-M, McBride EW, Quinn SM, Kopin AS. A single amino acid of cholecystokinin-B/gastrin receptor determines specificity for non-peptide antagonists. Nature 1993;362:348-350.
60. Ding X-Q, Miller LJ. Characterization of the type A cholecystokinin receptor hormone-binding domain: Use of contrasting and complementary methodologies. Peptides 2001;22:1223-1228.
61. Bläker M, Ren Y, Gordon MC, Hsu JE, Beinborn M, Kopin AS. Mutations within the cholecystokinin-B/gastrin receptor ligand 'Pocket' interconvert the functions of nonpeptide agonists and antagonists. Mol Pharmacol 1998;54:857-863.
62. Kopin AS, McBride EW, Schaffer K, Beinborn M. CCK receptor polymorphisms: An illustration of emerging themes in pharmacogenomics. Trends Pharmacol Sci 2000;21:346-352.
63. Tachikawa H, Harada S, Kawanissi Y, Okubo T, Shiraishi H. Novel polymorphism in the promoter and coding regions of the human cholecystokinin B receptor gene: An association analysis with schizophrenia. Am J Med Genet 1999;88:700-7004.
64. Fujii C, Harada S, Ohkoshi N, Hayashi A, Yoshizawa K, Ishizuka C, Nakamura T. Association between polymorphism of the cholecystokinin gene and idiopathic Parkinson's disease. Clin Genet 1999;56:394-399.
65. Funakoshi A, Miyasaka K, Matsumoto H, Yamamori S, Takiguchi S, Kataoka K, Takata Y, Matsusue K, Kono A, Shimokata H. Gene structure of human cholecystokinin (CCK) type-A receptor: Body fat content is related to CCK type-A receptor promoter polymorphism. FEBS Lett 2000;466:264-266.
66. Talkad VD, Fortune KP, Pollo DA, Shah GN, Wank SA, Gardner JD. Direct demostration of three different states of the pancreatic cholecystokinin receptor. Proc Natl Acad Sci USA 1994;91:1868-1872.
67. Li Y, Zhu J, Owyang C. Electrical physiological evidence for high- and low-affinity vagal CCK-A receptors. Am J Physiol 1999;277:G469-G477.
68. Harper EA, Roberts SP, Shankley NP, Black JW. Analysis of variations in L-365,260 competition curves in radioligand binding assays. Br J Pharmacol 1996;118:1717-1726.
69. Harper EA, Shankley NP, Black JW. Characterization of the binding of a novel radioligand to CCKB/gastrin receptors in membranes from rat cerebral cortex. Br J Pharmacol 1999;126:1504-1512.
70. Harper EA, Griffin EP, Shankley NP, Black JW. Analysis of the behaviour of selected CCKB/gastrin receptor antagonists in radioligand binding assays performed in mouse and rat cerebral cortex. Br J Pharmacol 1999;126:1496-1503.
71. Derrien M, McCort-Tranchepain I, Ducos B, Roques BP, Durieux C. Heterogeneity of CCK-B receptors involved in animal models of anxiety. Pharmacol Biochem Behav 1994;49:133-141.
72. Léna I, Simon H, Roques BP, Daugé V. Opposing effects of two CCK-B agonists on the retrieval phase of a two-trial memory task after systemic injection in the rat. Neuropharmacol 1999;38:543-553.
73. Freidinger RM. Cholecystokinin and gastrin antagonists. Med Res Rev 1989;9:271-290.
74. Woodruff GN, Hughes J. Cholecystokinin antagonists. Annu Rev Pharmacol Toxicol 1991;31:469-501.
75. Nadzan AM, Kerwin JF. Cholecystokinin agonists and antagonists. Annual Reports in Medicinal Chemistry 1991;26:191-201.
76. Wettstein JG, Bueno L, Junien JL. CCK antagonists: Pharmacology and therapeutic interest. Pharmac Ther 1994:62:267-182.
77. D'Amato M, Rovati LC. Cholecystokinin-A receptor antagonists: Therapies for gastrointestinal disorders. Exp Opin Invest Drugs 1997;6:819-836.
78. B/gastrin receptor antagonists as potential drugs for peptic ulcer therapy. Dug Discov Today 1997;2:283-293.
79. Dunlop J. CCK receptor antagonists. Gen Pharmac 1998;4:519-524.
80. de Tullio P, Delarge J, Pirotte B. Recent advances in the chemistry of cholecystokinin receptor ligands (agonists and antagonists). Curr Med Chem 1999;6:433-455.
81. Chambers MS, Fletcher SR. CCK-B antagonists in the control of anxiety and gastric acid secretion. In: King FD, Oxford AW, editors. Progress in Medicinal Chemistry, Vol 37. Oxford: Elsevier Science; 2000. p 45-81.
82. de Tullio P, Delarge J, Pirotte B. Therapeutic and chemical developments of cholecystokinin receptor ligands. Exp Opin Invest Drugs 2000;9:129-146.
83. 2receptor antagonists. Exp Opin Ther Patents 2001;11:445-462.
84. Jensen RT, Jones AW, Gardner JD. COOH-Terminal fragments of cholecystokinin. A new class of cholecystokinin receptor antagonists. Biochim Biophys Acta 1983;757:250-258.
85. Martinez J, Magous R, Lignon MF, Laur J, Castro B, Bali JP. Synthesis and biological activity of new peptide segments of gastrin exhibiting gastrin antagonist property. J Med Chem 1984;27:1597-1601.
86. Sparkel M, Martinez J, Briet C, Jensen RT, Gardner JD. Cholecystokinin-27-32-amide, a member of a new class of cholecystokinin receptor antagonists. J Biol Chem 1983;258:6746-6749.
87. 2 C-terminal hexapeptide of cholecystokinin showing gastrin antagonist activity. Int J Peptide Protein Res 1986;27:386-393.
88. 2 and derivatives: A new family of CCK antagonists. J Med Chem 1990;33:3199-3204.
89. Lignon MF, Galas MC, Rodriguez M, Laur J, Aumelas A, Martinez J. A synthetic peptide derivative that is a cholecystokinin receptor antagonist. J Biol Chem 1987;262:7226-7231.
90. Boomgaarden M, Henklein P, Morgenstern R, Sohr R, Ott T, Martinez J. Synthesis and biological activity of CCK peptides with antagonist activity for CCK-A-receptor. Eur J Med Chem 1992;27:955-959.
91. 4 derivatives. J Med Chem 1993;36:166-172.
92. Martinez J, Bali JP, Rodriguez M, Castro B, Magous R, Laur J. Synthesis and biological activities of some pseudo-peptide analogues of tetragastrin: The importance of the peptide backbone. J Med Chem 1985;28:1874-1879.
93. Herrero S, Suárez-Gea ML, González-Muñiz R, García-López MT, Herranz R, Ballaz S, Barber A, Fortuño A, Del Río J. Pseudopeptide CCK-4 analogues incorporating the ψ[CH(CN)NH] peptide bond surrogate. Bioorg. Med Chem Lett 1997;7:855-860.
94. 29 region. Eur J Pharmacol 1990;186:213-222.
95. Goëtz MA, Lopez M, Monaghan RL, Chang RSL, Lotti VJ, Chen TB. Asperlicin, a novel non-peptidal cholecystokinin antagonist from Aspergillus alliaceus. Fermentation, isolation and biological properties. J Antibiot 1985;38:1633-1637.
96. Chang RS, Lotti VJ, Monaghan RL, Birnbaum J, Stapley EO, Goetz MA, Albers-Schonberg G, Patchett AA, Liesch JM, Hensens OD, Springer JP. A potent nonpeptide cholecystokinin antagonist selective for peripheral tissues isolated from Aspergillus alliaceus. Science 1985;230:177-179.
97. Rovati AL, Casula PL, Da Re G. Pharmacological and experimental toxicology of a new non-anticholinergic product with antisecretory and gastroprotective activity (CR 242, xylamide-Milid). Minerva Med 1967;58:3656-3670.
98. Rovati AL. Inhibition of gastric secretion by anti-gastrinic and H2-blocking agents. Scand J Gastroenterol Suppl 1976;42:113-118.
99. Hahne WF, Jensen RT, Lemp GF, Gardner JD. Proglumide and benzotript: Members of a different class of cholecystokinin receptor antagonists. Proc Natl Acad Sci USA 1981;78:6304-6308.
100. Jensen RT, Jones SW, Gardner JD. Structure-function studies of N-acyl derivatives of tryptophan that function as specific cholecystokinin receptor antagonists. Biochim Biophys Acta 1983;761:269-277.
101. Maton PN, Sutliff VE, Jensen RT, Gardner JD. Carbobenzoxy amino acids: Structural requirements for cholecystokinin receptor antagonist activity. Am J Physiol. 1985;248:G479-G484.
102. Makovec F, Chiste R, Bani M, Revel L, Stnikar I, Rovati AL. New glutamic and aspartic derivatives with potent CCK-antagonistic activity. Eur J Med Chem 1986;21:9-20.
103. Makovec F, Bani M, Cereda R, Chisté R, Pacini MA, Revel L, Rovati LA, Rovati LC. Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists. Arzneimittelforschung 1987;37:1265-1268.
104. Setnikar I, Bani M, Cereda R, Chisté R, Makovec F, Pacini MA, Revel L, Rovati LC, Rovati LA. Pharmacological characterization of a new potent and specific nonpolypeptide cholecystokinin antagonist. Arzneimittelforschung 1987;37:703-707.
105. Setnikar I, Bani M, Cereda R, Chisté R, Makovec F, Pacini MA, Revel L. Anticholecystokinin activities of loxiglumide. Arzneimittelforschung 1987;37:1168-1171.
106. Setnikar I, Chiste R, Makovec F, Rovati LC, Warrington SJ. Pharmacokinetics of loxiglumide after single intravenous or oral doses in man. Arzneimittelforschung 1988;38:716-720.
107. Setnikar I, Bani M, Cereda R, Chisté R, Makovec F, Pacini MA, Revel L. Loxiglumide protects against experimental pancreatitis. 1987;37:1172-1174.
108. Ochi K, Harada H, Satake K. Clinical evaluation of cholecystokinin-A-receptor antagonist (loxiglumide) for the treatment of acute pancreatitis. A preliminary clinical trial. Study Group of Loxiglumide in Japan. Digestion 1999;60(Suppl 1):81-85.
109. Gielkens HA, de Boer SY, Lam WF, Rovati LC, Lamers CB, Masclee AA. The role of cholecystokinin and the cholinergic system in intravenous amino acid-induced gall bladder emptying. Eur J Gastroenterol Hepatol 1997;9:1227-1231.
110. Schwizer W, Borovicka J, Kunz P, Fraser R, Kreiss C, D'Amato M, Crelier G, Boesiger P, Freíd M. Role of cholecystokinin in the regulation of liquid gastric emptying and gastric motility in humans: Studies with the CCK antagonist loxiglumide. Gut 1997;41:500-5044.
111. Mesquita MA, Thompson DG, Troncon LE, D'Amato M, Rovati LC, Barlow J. Effect of cholecystokinin - A receptor blockade on lipid-induced gastric relaxation in humans. Am J Physiol 1997;273:G118-123.
112. Trudgill NJ, Hussain FN, Moustafa M, Ajjan R, D'Amato M, Riley SA. The effect of cholecystokinin antagonism on postprandial lower oesophageal sphinter function in asymptomatic volunteers and patients with reflux disease. Aliment Pharmacol Ther 2001;15:1357-1364.
113. Persiani S, D'Amato M, Makovec F, Tavares IA, Bishai PM, Rovati LC. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males. Int J Clin Pharmacol Ther 2002;40:198-206.
114. Varga G. Dexloxiglumide Rotta Research Lab. Curr Opin Investig Drugs 2002;3:621-626.
115. Kerwin JF, Nadzan AM, Kopecka H, Lin C W, Miller T, Witte D, Burt S. Hybrid cholecistokinin (CCK) antagonists: New implications in the design and modification of CCK antagonists. J Med Chem 1989;32:739-742.
116. Freidinger RM, Whitter WL, Gould NP, Holloway MK, Chang RSL, Lotti VJ. Novel glutamic acid derived cholecystokinin receptor ligands. J Med Chem 1990;33:591-595.
117. Kerwin JF, Wagenaar F, Kopecka H, Lin CW, Miller T, Witte D, Stashko M, Nadzan AM. Cholecystokinin antagonists: (R)-tryptophan-based hybrid antagonists of high affinity and selectivity for CCK-A receptors. J Med Chem 1991;34:3350-3359.
118. Yamazi Y, Akahane M, Kobayashi M, Kitazawa M, Kurashina Y, Iizuka K. Pharmacological profile of KSG-504, a new cholecystokinin-A-receptor antagonist. Jpn J Pharmacol 1993;63:219-225.
119. Hull RA, Shankley NP, Harper EA, Gerkowitch VP, Black JW. 2-Naphthalenesulphonyl-L-aspartyl-(2-phenyl)amide (2-NAP) a selective cholecystokinin CCKA-receptor antagonist. Br J Pharmacol 1993;108:734-740.
120. Goursaud AP, Nowak R. 2-NAP, a peripheral CCK-A receptor antagonist, modulates the development of a preference for the mother by the newborn lamb. Pharmacol Biochem Behav 2000;67:603-611.
121. Makovec F, Peris W, Revel L, Giovanetti R, Mennuni L, Rovati LC. Structure-antigastrin activity relationships of new (R)-4-benzamido-5-oxopentanoic acid derivatives. J Med Chem 1992;35:28-38.
122. Revel L, Ferrari F, Makovec F, Rovati LC, Impicciatore M. Characterization of antigastrin activity in vivo of CR 2194, a new R-4-benzamido-5-oxo-pentanoic acid derivative. Eur J Pharmacol. 1992;216:217-224.
123. B/gastrin-receptor antagonist, on gastrin-stimulated acid secretion in man. Gastroenterology 1994;106(Suppl):Abstract A50.
124. Beltinger J, Hidelbrand P, Drewe J, Christ A, Hlobil K, Ritz M, D'Amato M, Rovati L, Beglinger C. Effects of spiroglumide, a gastrin receptor antagonist, on acid secretion in humans. Eur J Clin Invest. 1999;29:153-159.
125. Makovec F, Peris W, Frigerio S, Giovanetti R, Letari O, Mennuni L, Revel L. Structure-antigastrin activity relationships of new spiroglumide amido acid derivatives. J Med Chem 1996;39:135-142.
126. Rovati LC, D'Amato M, Peris W, Revel L, Makovec F. Selectivity and potency of new basic CCK-B antagonists. Ann NY Acad Sci 1994;713:395-397.
127. B antagonist. Eur J Pharmacol 1999;369:81-90.
128. B receptor antagonist with anxiolytic-like activity. Behav Pharmacol 1998;9:183-194.
129. Fontana MG, Donato F, Villanacci V, Ghirardi M, Moneghini D, Di Betta E, Salerni B. Inhibitory effect of a gastrin receptor antagonist, CR2945, on 1, 2-dimethylhydrazine-induced colorectal cancer in mice. Eur Surg Res. 1999;31:406-411.
130. Bock MG, DiPardo RM, Rittle KE, Evans BE; Freidinger RM, Veber DF, Chang RSL, Chen T, Keegan ME, Lotti VJ. Cholecystokinin antagonists. Synthesis of asperlicin analogues with improved potency and water solubility. J Med Chem 1986;29:1941-1945.
131. Evans BE, Rittle KE, Bock MG, DiPardo RM, Whitter WL, Gould NP, Lundell GF, Homnick CF, Veber DF, Anderson PS, Chang RSL, Lotti VJ, Cerino DJ, Chen TB, King PJ, Kunkel KA, Springer JP, Hirshfield J. Design of nonpeptidal ligands for peptide receptor: Cholecystokinin antagonists. J Med Chem 1987;30:1229-1239.
132. Evans BE, Bock MG, Rittle KE, DiPardo RM, Whitter WL, Veber DF, Anderson PS, Freidinger RM. Design of potent, orally effective, nonpeptidal antagonists of the peptide hormone cholecystokinin. Proc Natl Acad Sci USA 1986;83:4918-4922.
133. Evans BE, Rittle KE, Bock MG, DiPardo RM, Freidinger RM, Whitter WL, Lundell GF, Veber DF, Anderson PS, Chang RSL, Lotti VJ, Cerino DJ, Chen TB, Kling PJ, Kunkel KA, Springer JP, Hirshfield J. Methods for drug discovery: Development of potent, selective orally effective cholecystokinin antagonists. J Med Chem 1988;31:2235-2246.
134. Pullen RG, Hodgson OJ. Penetration of diazepam and the non-peptide CCK antagonist, L-364,718, into rat brain. J Pharm Pharmacol 1987;39:863-864.
135. Woltman TA, Hulce M, Reidelberger RD. Relative blood-brain barrier permeabilties of the cholecystokinin receptor antagonists devazepide and A-65186 in rats. J Pharm Pharmacol 1999;51:917-920.
136. Cantor P, Mortensen PE, Myhre J, Gjorup I, Worning H, Stahl E, Survill TT. The effect of the cholecystokinin receptor antagonist MK-329 on meal-stimulated pancreaticobiliary output in humans. Gastroenterology 1992;102:1742-1751.
137. Cantor P, Olsen O, Gertz BJ, Gjorup I, Worning H. Inhibition of cholecystokinin-stimulated pancreaticobiliary output in man by the cholecystokinin receptor antagonist MK-329. Scand J Gastroenterol 1991;26:627-637.
138. Liddle RA, Gertz BJ, Kanayama S, Beccaria L, Coker LD, Turnbull TA, Morita ET. Effects of a novel cholecystokinin (CCK) receptor antagonist, MK-329, on gall bladder contraction and gastric emptying in humans. Implications for the physiology of CCK. J Clin Invest 1989;84:1220-1225.
139. Iversen LL, Dourish CT, Iversen SD. Cholecystokinin receptors: Synthetic antagonists with selectivity for receptor subtypes and possible clinical applications. Biochem Soc Trans 1991;19:913-914.
140. Ohlsson B, Axelson J, Rehfeld JF, Ihse I. Devazepide-induced hyperplasia in the rat liver and bile ducts. Eur Surg Res 1996;28:299-305.
141. Satoh Y, Matsuo T, Sogabe H, Itoh H, Tada T, Kinoshita T, Yoshida K, Takaya T. Studies on a novel, potent and orally effective cholecystokinin A antagonist, FK-480. Synthesis and structure-activity relationships of FK-480 and related compounds. Chem Pharm Bull (Tokyo) 1994;42:2071-2083.
142. Ito H, Sogabe H, Nakarai T, Sato Y, Tomoi M, Kadowaki M, Matsuo M, Tokoro K, Yoshida K. Pharmacological profile of FK480, a novel cholecystokinin type-A receptor antagonist: Comparison to loxiglumide. J Pharmacol Exp Ther 1994;268:571-575.
143. 1H-indole-2-carboxamides as cholecystokinin antagonists. Ger Offen 1990; Pat Application: DE 89-3907390.
144. Zabielski R, Lesniewska V, Borlak J, Gregory PC, Kiela P, Pierzynowski SG, Barej W. Effects of intraduodenal administration of tarazepide on pancreatic secretion and duodenal EMG in neonatal calves. Regul Pept 1998;78:113-123.
145. Bock MG, DiPardo R, Evans BE, Rittle KE, Whitter WL, Veber DF, Anderson PS, Freidinger RM. Benzodiazepine gastrin and brain cholecystokinin receptor ligands: L-365,260. J Med Chem 1989;32:13-16.
146. Lotti VJ, Chang RS. A new potent and selective non-peptide gastrin antagonist and brain cholecystokinin receptor (CCK-B) ligand: L-365,260. Eur J Pharmacol 1989;162:273-280.
147. Murphy MG, Sytnik B, Kovacs TO, Mertz H, Ewanik D, Shingo S, Lin JH, Gertz BJ, Walsh JH. The gastrin-receptor antagonist L-365,260 inhibits stimulated acid secretion in humans. Clin Pharmacol Ther 1993;54:533-539.
148. Bradwejn J, Koszycki D, Couetoux du Tertre A, van Megen H, den Boer J, Westenberg H. The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Arch Gen Psychiatry 1994;51:486-493.
149. Westenberg HGM, Van Megen HJGM, Den Boer JA. Effects of the cholecystokinin-B antagonist L-365,260 on lactate-induced panic disorder (PD) patients. Psychopharmacol Bull 1994;30:644.
150. Lines C, Challenor J, Traub M. Cholecystokinin and anxiety in normal volunteers: An investigation of the anxiogenic properties of pentagastrin and reversal by the cholecystokinin receptor subtype B antagonist L-365,260. Br J Clin Pharmacol 1995;39:235-242.
151. B antagonist, in panic disorder. Biol Psychiatry 1995;37:462-466.
152. Chen IW, Dorley JM, Ramjit HG, Pitzenberger SM, Lin JH. Physiological disposition and metabolism of L-365,260, a potent antagonist of brain cholecystokinin receptor, in laboratory animals. Drug Metab Dispos 1992;20:390-395.
153. Lin JH, Storey DE, Chen IW, Xu X. Improved oral absorption of L-365,260, a poorly soluble drug. Biopharm Drug Dispos 1996;17:1-15.
154. Bock MG, DiPardo RM, Evans BE, Rittle KE, Whitter WL, Garsky VM, Gilbert KF, Leighton JL, Carson KL, Mellin EC, Veber DF, Chang RDL, Lotti VJ, Freedman SB, Smith AJ, Patel S, Anderson PS, Freidinger RM. Development of 1,4-benzodiazepine cholecystokinin type B antagonists. J Med Chem 1993;36:4276-4292.
155. B/gastrin receptor. Bioorg Med Chem Lett 1993;3:1919-1924.
156. Bock MG, DiPardo RM, Mellin EC, Newton RC, Veber DF, Freedman SB, Smith AJ, Patel S, Kemp JA, Marshall GR, Fletcher AE, Chapman KL, Anderson PS, Freidinger RM. Second-generation benzodiazepine CCK-B antagonists. Development of subnanomolar analogs with selectivity and water solubility. J Med Chem 1994;37:722-724.
157. Castro JL, Ball RG, Broughton HB, Russell MG, Rathbone D, Watt AP, Baker R, Chapman KL, Fletcher AE, Patel S, Smith AJ, Marshall GR, Ryecroft W, Matassa VG. Controlled modification of acidity in cholecystokinin B receptor antagonists: N-(1,4-benzodiazepin-3-yl)-N′-[3-(tetrazol-5-ylamino) phenyl]ureas. J Med Chem 1996;39:842-849.
158. B/gastrin receptor antagonists containing a cationic solubilising group. J Med Chem 1994;37:719-721.
159. Castro JL, Broughton HB, Russell MG, Rathbone D, Watt AP, Ball RG, Chapman KL, Patel S, Smith AJ, Marshall GR, Matassa VG. 5-(Piperidin-2-yl)- and 5-(homopiperidin-2-yl)-1,4-benzodiazepines: High-affinity, basic ligands for the cholecystokinin-B receptor. J Med Chem 1997;40:2491-2501.
160. B/gastrin receptor antagonists. Bioorg Med Chem Lett 1995;5:3023-3026.
161. Patel S, Smith AJ, Chapman KL, Fletcher AE, Kemp JA, Marshall GR, Hargreaves RJ, Ryecroft W, Iversen LL, Iversen SD, et al. Biological properties of the benzodiazepine amidine derivative L-740,093, a cholecystokinin-B/gastrin receptor antagonist with high affinity in vitro and high potency in vivo. Mol Pharmacol 1994;46:943-948.
162. Selnick HG, Liverton NJ, Baldwin JJ, Butcher JW, Claremon DA, Elliott JM, Freidinger RM, King SA, Libby BE, McIntyre CJ, Pribush DA, Remy DC, Smith GR, Tebben AJ, Jurkiewicz NK, Lynch JJ, Salata JJ, Sanguinetti MC, Siegl PK, Slaughter DE, Vyas K. Class III antiarrhythmic activity in vivo by selective blockade of the slowly activating cardiac delayed rectifier potassium current
163. Satoh M, Kondoh Y, Okamoto Y, Nishida A, Miyata K, Ohta M, Mase T, Murase K. New 1,4-benzodiazepin-2-one derivatives as gastrin/cholecystokinin-B antagonists. Chem Pharm Bull 1995;43:2159-2167.
164. Nishida A, Miyata K, Tsutsumi R, Yuki H, Akuzawa S, Kobayashi A, Kamato T, Ito H, Yamano M, Katuyama Y, et al. Pharmacological profile of (R)-1-[2,3-dihydro-1-(2′-methylphenacyl)-2-oxo-5-phenyl-1H-1, 4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo. J Pharmacol Exp Ther 1994;269:725-731.
165. Yano K, Kajiyama A, Yamazaki S, Matsumura Y, Watanabe K, Yamamoto K. In vitro stability and in vivo absorption studies of colloidal particles formed from a solid dispersion system. Chem Pharm Bull (Tokyo) 1996;44:2309-2313.
166. Nishida A, Takinami Y, Yuki H, Kobayashi A, Akuzawa S, Kamato T, Ito H, Yamano M, Nagakura Y, Miyata K. YM022 [(R)-1-[2,3-dihydro-1-(2′-methylphenacyl)-2-oxo-5-phenyl-1H-1, 4-benzodiazepin-3-y1]-3-(3-methylphenyl)urea], a potent and selective gastrin/cholecystokinin-B receptor antagonist, prevents gastric and duodenal lesions in rats. J Pharmacol Exp Ther 1994;270:1256-1261.
167. Nishida A, Kobayashi-Uchida A, Akuzawa S, Takinami Y, Shishido T, Kamato T, Ito H, Yamano M, Yuki H, Nagakura Y, et al. Gastrin receptor antagonist YM022 prevents hypersecretion after long-term acid suppression. Am J Physiol 1995;269:G699-705.
168. Semple G, Ryder H, Rooker DP, Batt AR, Kendrick DA, Szelke M, Ohta M, Satoh M, Nishida A, Akuzawa S, Miyata K. (3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1, 4-benzodiazepin-3-y1)-N′-(3-(methylamino)phenyl)urea (YF476): A potent and orally active gastrin/CCK-B antagonist. J Med Chem 1997;40:331-341.
169. Takinami Y, Yuki H, Nishida A, Akuzawa S, Uchida A, Takemoto Y, Ohta M, Satoh M, Semple G, Miyata K. YF476 is a new potent and selective gastrin/cholecystokinin-B receptor antagonist in vitro and in vivo. Aliment Pharmacol Ther 1997;11:113-120.
170. Schmassmann A, Reubi JC. Cholecystokinin-B/gastrin receptors enhance wound healing in the rat gastric mucosa. J Clin Invest 2000;106:1021-1029.
171. Kitano M, Norlen P, Ding XQ, Nakamura S, Hakanson R. Long-lasting cholecystokinin(2) receptor blockade after a single subcutaneous injection of YF476 or YM022. Br J Pharmacol 2000;130:699-705.
172. 2 and gastrin receptor antagonists. Bioorg Med Chem Lett 1996;6:1421-1426.
173. 2 and gastrin antagonists. Bioorg Med Chem Lett 1996;6:1427-1430.
174. 2 and gastrin receptor antagonist. Chem Pharm Bull 1997;45:116-124.
175. Satoh Y, Tabuchi S, Mitsui H. Design of dual CCK-A and CCK-B receptor antagonists. Drugs of the Future 1997;22:117-1131.
176. Tabuchi S, Nakanishi I, Satoh Y. Relationship between dihedral angles of N1 and C9 substituents in 1,4-benzodiazepines and dual cholecystokinin-A and -B antagonistic activities. Bioorg Med Chem Lett 1998;8:1449-1454.
177. Tabuchi S, Ito H, Sogabe H, Kuno M, Kinoshita T, Katumi I, Yamamoto N, Mitsui H, Satoh Y. Dual CCK-A and CCK-B receptor antagonists (II). Preparation and structure activity relationships of 5-alkyl-9-methyl-1,4-benzodiazepines and discovery of FR208419. Chem Pharm Bull 2000;48:1-15.
178. Bock MG, DiPardo RM, Veber DF, Chang RSL, Lotti VJ, Freedman SB, Freidinger RM. Benzolactams as non-peptide cholecystokinin receptor ligands. Bioorg Med Chem Lett 1993;3:871-874.
179. Lowe JA 3rd, Hageman DL, Drozda SE, McLean S, Bryce DK, Crawford RT, Zorn S, Morrone J, Bordner J. 5-Phenyl-3-ureidobenzazepin-2-ones as cholecystokinin-B receptor antagonists. J Med Chem 1994;37:3789-3811.
180. Lowe JA, Drozda AE, Mclean S, Bryce DK, Crwford RT. A water soluble benzazepine cholecystokinin-B receptor antagonist. Bioorg Med Chem Lett 1995;5:1933-1936.
181. Aquino CJ, Armour DR, Berman JM, Birkemo LS, Carr RA, Croom DK, Dezube M, Dougherty RW Jr, Ervin GN, Grizzle MK, Head JE, Hirst GC, James MK, Johnson MF, Miller LJ, Queen KL, Rimele TJ, Smith DN, Sugg EE. Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity. 1. Optimization of the agonist "trigger". J Med Chem 1996;39:562-569.
182. Ursini A, Capelli AM, Carr RA, Cassara P, Corsi M, Curcuruto O, Curotto G, Dal Cin M, Davalli S, Donati D, Feriani A, Finch H, Finizia G, Gaviraghi G, Marien M, Pentassuglia G, Polinelli S, Ratti E, Reggiani AM, Tarzia G, Tedesco G, Tranquillini ME, Trist DG, Van Amsterdam FT, Reggiani A. Synthesis and SAR of new 5-phenyl-3-ureido-1,5-benzodiazepines as cholecystokinin-B receptor antagonists. J Med Chem 2000;43:3596-3613.
183. Reggiani A, Gerrard PA, Maraia G, Melotto S, Ratti E, Gaviraghi G, Trist DG. Anxiolytic activity of GV150013, a new potent and selective cholecystokinin-B (CCK-B) antagonist. Br J Pharmacol 1995;114(Proceedings Suppl):92P.
184. Crespi F. Cholecystokinin-B (CCK-B) receptor antagonists improve "aged" sleep: A new class of sleep modulators? Methods Find Exp Clin Pharmacol 1999;21:31-38.
185. B antagonists. Bioorg Med Chem Lett 1997;7:281-286.
186. Hagishita A, Seno K, Kamata S, Haga N, Ishihara Y, Ishikawa M, Shimamura M. Potent and subtype-selective CCK-B/gastrin receptor antagonists: 2,4-Dioxo-1,5-benzodiazepines with a plane of symmetry. Bioorg Med Chem 1997;5:1433-1446.
187. Bohme GA, Bertrand P, Guyon C, Capet M, Pendley C, Stutzmann JM, Doble A, Dubroeucq MC, Martin G, Blanchard JC. The ureidoacetamides, a novel family of non-peptide CCK-B/gastrin antagonists. Ann N Y Acad Sci 1994;713:118-120.
188. Bertrand P, Bohme GA, Durieux C, Guyon C, Capet M, Jeantaud B, Boudeau P, Ducos B, Pendley CE, Martin GE, et al. Pharmacological properties of ureido-acetamides, new potent and selective non-peptide CCKB/gastrin receptor antagonists. Eur J Pharmacol 1994;262:233-245.
189. Pendley CE, Fitzpatrick LR, Capolino AJ, Davis MA, Esterline NJ, Jakubowska A, Bertrand P, Guyon C, Dubroeucq MC, Martin GE. RP 73870, a gastrin/cholecystokinin-B receptor antagonist with potent anti-ulcer activity in the rat. J Pharmacol Exp Ther 1995;273:1015-1022.
190. Hagishita S, Murakami Y, Seno K, Kamata S, Haga N, Konoike T, Kanda Y, Kiyama R, Shiota T, Ishihara Y, Ishikawa M, Shimamura M, Abe K, Yoshimura K. Synthesis and pharmacological properties of ureidomethylcarbamoylphenylketone derivatives. A new potent and subtype-selective nonpeptide CCK-B/gastrin receptor antagonist, S-0509. Bioorg Med Chem 1997;5:1695-1714.
191. Takeda Y, Kawagoe K, Yokomizo A, Yokomizo Y, Hosokami T, Ogihara Y, Honda Y, Yokohama S. Synthesis of phenoxyacetic acid derivatives as highly potent antagonists of gastrin/cholecystokinin-B receptors. Chem Pharm Bull (Tokyo) 1998;46:434-444.
192. Takeda Y, Kawagoe K, Yokomizo A, Yokomizo Y, Hosokami T, Shimoto Y, Tabuchi Y, Ogihara Y, Otsubo R, Honda Y, Yokohama S. Synthesis of phenoxyacetic acid derivatives as highly potent antagonists of gastrin/cholecystokinin-B receptors. II. Chem Pharm Bull (Tokyo) 1998;46:951-961.
193. Takeda Y, Kawagoe K, Yokomizo A, Yokomizo Y, Hosokami T, Shimoto Y, Tabuchi Y, Ogihara Y, Honda Y, Kawarabayashi K, Iseri M, Yokohama S. Synthesis of phenoxyacetic acid derivatives as highly potent antagonists of gastrin/cholecystokinin-B receptors. III. Chem Pharm Bull (Tokyo) 1999;47:755-771.
194. Yu MJ, Thrasher KJ, McCowan JR, Mason NR, Mendelsohn LG. Quinazolinone cholecystokinin-B receptor ligands. J Med Chem 1991;34:1505-1508.
195. Rasmussen K, Yu MJ, Czachura JF. Quinazolinone cholecystokinin (CCK)-B antagonists decrease midbrain dopamine unit activity. Synapse 1994;17:278-282.
196. Yu MJ, McCowan JR, Mason NR, Deeter JB, Mendelsohn LG. Synthesis and X-ray crystallographic analysis of quinazolinone cholecystokinin/gastrin receptor ligands. J Med Chem 1992;35:2534-2542.
197. Padia JK, Chilvers H, Daum P, Pinnock R, Suman-Chauhan N, Webdale L, Trivedi BK. Design and synthesis of novel nonpeptide CCK-B receptor antagonists. Bioorg Med Chem Lett 1997;7:805-810.
198. Padia JK, Field M, Hinton J, Meecham K, Pablo J, Pinnock R, Roth BD, Singh L, Suman-Chauhan N, Trivedi BK, Webdale L. Novel nonpeptide CCK-B antagonists: Design and development of quinazolinone derivatives as potent, selective, and orally active CCK-B antagonists. J Med Chem 1998;41:1042-1049.
199. Horwell DC, Beeby A, Clark CR, Hughes J. Synthesis and binding affinities of analogues of cholecystokinin-(30-33) as probes for central nervous system cholecystokinin receptors. J Med Chem 1987;30:729-732.
200. Horwell DC, Birchmore B, Boden PR, Higginbottom M, Ping Ho Y, Hughes J, Hunter JC, Richardson RS. α-Methyl tryptophanylphenylalanines and their arylethylamine "dipeptoid" analogues of the tetrapeptide cholecystokinin (30-33). Eur J Med Chem 1990;25:53-60.
201. Augelli-Szafran CE, Purchase TS, Roth BD, Tait B, Trivedi BK, Wilson M, Suman-Chauhan N, Webdale L. SAR study of the indole moiety of CI-988, a potent and selective CCK-B antagonist. Bioorg Med Chem Lett 1997;7:2009-2014.
202. Horwell DC, Hughes J, Hunter JC, Pritchard MC, Richardson RS, Roberts E, Woodruff GN. Rationally designed "dipeptoid" analogues of CCK. α-Methyltryptophan derivatives as highly selective and orally active gastrin and CCK-B antagonists with potent anxiolytic properties. J Med Chem 1991;34:404-414.
203. Drysdale MJ, Pritchard MC, Horwell DC. Rationally designed "dipeptoid" analogues of CCK. Acid mimics of the potent and selective non-peptide CCK-B receptor antagonist CI-988. J Med Chem 1992;35: 2573-2581.
204. Hughes J, Boden P, Costall B, Domeney A, Kelly E, Horwell DC, Hunter JC, Pinnock RD, Woodruff GN. Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc Natl Acad Sci USA 1990;87:6728-6732.
205. Adams JB, Pyke RE, Costa J, Cutler NR, Schweizer E, Wilcox CS, Wisselink PG, Greiner M, Pierce MW, Pande AC. A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder. J Clin Psychopharmacol 1995;15:428-434.
206. van Megen HJ, Westenberg HG, den Boer JA, Slaap B, van Es-Radhakishun F, Pande AC. The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients. Psychopharmacology 1997;129:243-248.
207. Goddard AW, Woods SW, Money R, Pande AC, Charney DS, Goodman WK, Heninger GR, Price LH. Effects of the CCK(B) antagonist CI-988 on responses to mCPP in generalized anxiety disorder. Psychiatry Res 1999;85:225-240.
208. Pande AC, Greiner M, Adams JB, Lydiard RB, Pierce MW. Placebo-controlled trial of the CCK-B antagonist, CI-988, in panic disorder. Biol Psychiatry 1999;46:860-862.
209. Cowley DS, Adams JB, Pyke RE, Cook J, Zaccharias P, Wingerson D, Roy-Byrne PP. Effect of CI-988, a cholecystokinin-B receptor antagonist, on lactate-induced panic. Biol Psychiatry 1996;40:550-552.
210. Bradwejn J, Koszycki D, Paradis M, Reece P, Hinton J, Sedman A. Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers. Biol Psychiatry 1995;38:742-746.
211. Ding X-Q, Chen D, Håkanson R. Cholecystokinin-B/gastrin receptor ligands of the dipeptoid series act as agonists on histidine decarboxylase in rat stomach enterochromaffinlike cells. Pharmacol Toxicol 1995;76(Suppl IV):81.
212. Marvik R, Sandvik AK, Waldum HL. Evaluation of biologic gastrin activity of compound CI-988 in the isolated, vascularly perfused rat stomach. Scand J Gastroenterol 1997;32:519-522.
213. Patel S, Chapman KL, Smith AJ, Bailey I, Freedman SB. Are radioligand antagonist/agonist binding ratios in rat pancreas predictive of functional efficacy of cholecystokinin receptor agonists and antagonists? Regul Pept 1996;65:29-35.
214. Coudore-Civiale MA, Courteix C, Boucher M, Meen M, Fialip J, Eschalier A, Ardid D. Potentiation of morphine and clomipramine analgesia by cholecystokinin-B antagonist CI-988 in diabetic rats. Neurosci Lett 2000;286:37-40.
215. Coudore-Civiale MA, Courteix C, Fialip J, Boucher M, Eschalier A. Spinal effect of the cholecystokinin-B receptor antagonist CI-988 on hyperalgesia, allodynia and morphine-induced analgesia in diabetic and mononeuropathic rats. Pain 2000;88:15-22.
216. Trivedi BK, Padia JK, Holmes A, Rose S, Wright DS, Hinton JP, Pritchard MC, Eden JM, Kneen C, Webdale L, Suman-Chauhan N, Boden P, Singh L, Field MJ, Hill D. Second generation "peptoid" CCK-B receptor antagonists: Identification and development of N-(adamantyloxycarbonyl)-α-methyl-(R)-tryptophan derivative (CI-1015) with an improved pharmacokinetic profile. J Med Chem 1998;41:38-45.
217. Trivedi BK, Hinton JP. CI-1015. An orally active CCK-B receptor antagonist with an improved pharmacokinetic profile. Pharm Biotechnol 1998;11:481-505.
218. Fincham CI, Higginbottom M, Hill DR, Horwell DC, O'Toole JC, Ratcliffe GS, Rees DC, Roberts E. Amide bond replacements incorporated into CCK-B selective "dipeptoids". J Med Chem 1992;35:1472-1484.
219. Boden PR, Higginbottom M, Hill DR, Horwell DC, Hughes J, Rees DC, Roberts E, Singh L, Suman-Chauhan N, Woodruff GN. Cholecystokinin dipeptoid antagonists: Design, synthesis, and anxiolytic profile of some novel CCK-A and CCK-B selective and "mixed" CCK-A/CCK-B antagonists. J Med Chem 1993;36:552-565.
220. Augelli-Szafran CE, Horwell DC, Kneen C, Ortwine DF, Pritchard MC, Purchase TS, Roth BD, Trivedi BK, Hill D, Suman-Chauhan N, Webdale L. Cholecystokinin B antagonists. Synthesis and quantitative structure-activity relationships of a series of C-terminal analogues of CI-988. Bioorg Med Chem 1996;4:1733-1745.
221. Hughes J, Dockray GJ, Hill D, Garcia L, Pritchard MC, Forster E, Toescu E, Woodruff G, Horwell DC. Characterization of novel peptoid agonists for the CCK-A receptor. Regul Pept 1996;65:15-21.
222. Fincham CI, Horwell DC, Ratcliffe GS, Rees DC. The use of a proline ring as a conformational restraint in CCK-B receptor "dipeptoids". Bioorg Med Chem Lett 1992;2:403-406.
223. Higginbottom M, Hill DR, Horwell DC, Mostafai E, Suman-Chauhan N, Roberts E. Conformationally restricted analogues of the potent CCK-B antagonist CI-988. Bioorg Med Chem 1993;1:209-217.
224. Bellier B, McCort-Tranchepain I, Ducos B, Danascimento S, Meudal H, Noble F, Garbay C, Roques BP. Synthesis and biological properties of new constrained CCK-B antagonists: Discrimination of two affinity states of the CCK-B receptor on transfected CHO cells. J Med Chem 1997;40:3947-3956.
225. Eden JM, Horwell DC, Pritchard MC. α,β-didehydrotryptophan as a surrogate for α-methyltryptophan in CCK 'peptoids' related to CI-988. Bioorg Med Chem Lett 1993;3:989-992.
226. De la Figuera N, Martín-Martínez M, Herranz R, García-López MT, Latorre M, Cenarruzabeitia E, Del Río J, González-Muñiz R. Highly constrained dipeptoid analogues containing a type II' β-type mimic as novel and selective CCK-A receptor ligands. Bioorg Med Chem Lett 1999;9:43-48.
227. 1 receptor antagonists. J Med Chem 2000;43:3770-3777.
228. Kalindjian SB, Bodkin MJ, Buck IM, Dunstone DJ, Low CM, McDonald IM, Pether MJ, Steel KI. A new class of non-peptidic cholecystokinin-B/gastrin receptor antagonists based on dibenzobicyclo[2.2.2]octane. J Med Chem 1994;37:3671-3673.
229. Kalindjian SB, Buck IM, Cushnir JR, Dunstone DJ, Hudson ML, Low CM, McDonald IM, Pether MJ, Steel KI, Tozer MJ. Improving the affinity and selectivity of a nonpeptide series of cholecystokinin-B/gastrin receptor antagonists based on the dibenzobicyclo[2.2.2] octane skeleton. J Med Chem 1995;38:4294-4302.
230. Kalindjian SB, Buck IM, Davies JM, Dunstone DJ, Hudson ML, Low CM, McDonald IM, Pether MJ, Steel KI, Tozer MJ, Vinter JG. Non-peptide cholecystokinin-B/gastrin receptor antagonists based on bicyclic, heteroaromatic skeletons. J Med Chem 1996;39:1806-1815.
231. Ding XQ, Lindstrom E, Hakanson R. Evaluation of three novel cholecystokinin-B/gastrin receptor antagonists: A study of their effects on rat stomach enterochromaffin-like cell activity. Pharmacol Toxicol 1997;81:232-237.
232. 2 receptor antagonists using isolated rat stomach ECL cells. Br J Pharmacol 1999;127:530-536.
233. Hakanson R, Ding XQ, Norlen P, Lindstrom E. CCK2 receptor antagonists: Pharmacological tools to study the gastrin-ECL cell-parietal cell axis. Regul Pept 1999;80:1-12.
234. 2 receptor antagonists containing the conformationally constrained phenylalanine derivatives, including the new amino acid Xic. Eur J Med Chem 2002;37:379-389.
235. McDonald IM, Dunstone DJ, Kalindjian SB, Linney ID, Low CM, Pether MJ, Steel KI, Tozer MJ, Vinter JG. 2,7-Dioxo-2,3,4,5,6,7-hexahydro-1H-benzo[h][1,4]diazonine as a new template for the design of CCK2 receptor antagonists. J Med Chem 2000;43:3518-3529.
236. Kalindjian SB, Dunstone DJ, Low CM, Pether MJ, Roberts SP, Tozer MJ, Watt GF, Shankley NP. Nonpeptide cholecystokinin-2 receptor agonists. J Med Chem 2001;44:1125-1133.
237. González-Muñiz R, Domínguez MJ, Martín-Martínez M, Herranz R, García-López MT, Barber A, Ballaz S, Del Río J. CCK-4 restricted analogues containing a 3-oxoindolizidine skeleton. Bioorg Med Chem Lett 1996;6:967-972.
238. Martín-Martínez M, Bartolomé-Nebreda JM, Gómez-Monterrey I, González-Muñiz R, García-López MT, Ballaz S, Barber A, Fortuño A, Del Río J, Herranz R. Synthesis and stereochemical structure-activity relationships of 1,3-dioxoperhydropyrido[1,2-c]-pyrimidine derivatives: Potent and selective cholecystokinin-A receptor antagonists. J Med Chem 1997;40:3402-3407.
239. A receptor antagonist with anxiolytic-like activity in animal models. Br J Pharmacol 1997;121: 759-767.
240. Woodruff GN, Hill DR, Boden P, Pinnock R, Singh L, Hughes J. Functional role of brain CCK receptors. Neuropeptides 1991;19(Suppl):45-56.
241. Hendrie CA, Dourish CT. Anxiolytic profile of the cholecystokinin antagonist devazepide in mice. Br J Pharmacol 1990;99:138P.
242. Hendrie CA, Neill JC, Shepherd JK, Dourish CT. The effects of CCKA and CCKB antagonists on activity in the black/white exploration model of anxiety in mice. Physiol Behav 1993;54:689-693.
243. Ravard S, Dourish CT. Cholecystokinin and anxiety. Trends Pharmacol Sci 1990;11:271-273.
244. 1 receptor antagonists: Structural modifications at the tryptophan domain. J Med Chem 1999;42:4659-4668.
245. 1 receptor antagonists: Structure-activity relationship studies on the substituent at N2-position. J Med Chem 2001;44:2219-2228.
246. 1 receptor antagonists: Structure-activity relationship studies on the central 1,3-dioxoperhydropyrido[1,2-c]pyrimidine scaffold. J Med Chem 2001;44:4196-4206.
247. 1 subtype receptor selectivity towards CCK2 receptors. Personal communication to the XVIIth International Symposium on Medicinal Chemistry, Barcelona, September 2002.
248. Howbert JJ, Lobb KL, Britton TC, Mason NR, Bruns RF. Diphenylpyrazolidinone and benzodiazepine cholecystokinin antagonists: A case of convergent evolution in medicinal chemistry. Bioorg Med Chem Lett 1993;5:875-880.
249. Ding XQ, Hakanson R. Evaluation of the specificity and potency of a series of cholecystokinin-B/gastrin receptor antagonists in vivo. Pharmacol Toxicol 1996;79:124-130.
250. Helton DR, Berger JE, Czachura JF, Rasmussen K, Kallman MJ. Central nervous system characterization of the new cholecystokininB antagonist LY288513. Pharmacol Biochem Behav 1996;53:493-502.
251. Izumi T, Inoue T, Tsuchiya K, Hashimoto S, Ohmori T, Koyama T. Effect of the selective CCKB receptor antagonist LY288513 on conditioned fear stress in rats. Eur J Pharmacol 1996;300:25-31.
252. Adamec RE, Shallow T, Budgell J. Blockade of CCK(B) but not CCK(A) receptors before and after the stress of predator exposure prevents lasting increases in anxiety-like behavior: Implications for anxiety associated with posttraumatic stress disorder. Behav Neurosci 1997;111:435-449.
253. Rasmussen K, Czachura JF, Kallman MJ, Helton DR. The CCK-B antagonist LY288513 blocks the effects of nicotine withdrawal on auditory startle. Neuroreport 1996;7:1050-1052.
254. Rasmussen K, Helton DR, Berger JE, Scearce E. The CCK-B antagonist LY288513 blocks diazepam-withdrawal-induced increases in auditory startle response. Ann N Y Acad Sci 1994;713:374-376.
255. Flynn DL, Villamil CI, Becker DP, Gullikson GW, Moummi C, Yang D-C. 1,3,4-trisubstituted pyrrolidinones as scaffolds for construction of peptidomimetic cholecystokinin antagonists. Bioorg Med Chem Lett 1992;2:1251-1256.
256. Lowe JA III, Qian W, Scott PJ, McLean S, Bryce DK, Crawford RT, Bordner J. 5,7-Diphenyl-3-ureidohexahydroazepin-2-ones as Cholecystokinin-B receptor ligands. Bioorg Med Chem Lett 1994;4:2877-2882.
257. B antagonist. Jpn J Pharmacol 1995;67(Suppl 1): Abstract P2-119.
258. B antagonist. Gastroenterology 1995;108(Suppl):A950.
259. Chiba T, Kinoshita Y, Sawada M, Kishi K, Baba A, Hoshino E. The role of endogenous gastrin in the development of enterochromaffin-like cell carcinoid tumors in Mastomys natalensis: A study with the specific gastrin receptor antagonist AG-041R. Yale J Biol Med 1998;71:247-255.
260. Kitamura H, Kato A, Esaki T. AG-041R, a novel indoline-2-one derivative, induces systemic cartilage hyperplasia in rats. Eur J Pharmacol 2001;418:225-230.
261. Ochi M, Kawasaki K, Kataoka H, Uchio Y, Nishi H. AG-041R, a gastrin/ CCK-B antagonist, stimulates chondrocyte proliferation and metabolism in vitro. Biochem Biophys Res Commun 2001;283:1118-1123.
262. Nakanishi T, Kawasaki K, Uchio Y, Kataoka H, Terashima M, Ochi M. AG-041R, a cholecystokinin-B/gastrin receptor antagonist, stimulates the repair of osteochondral defect in rabbit model. Eur J Pharmacol 2002;439:135-140.
263. Taniguchi H, Yazaki N, Endo T, Nagasaki M. Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vitro. Eur J Pharmacol 1996;304:147-154.
264. Taniguchi H, Yazaki N, Yomota E, Shikano T, Endo T, Nagasaki M. Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vivo. Eur J Pharmacol 1996;312:227-233.
265. Taniguchi H, Yomota E, Kume E, Shikano T, Endo T, Nagasaki M. Effect of T-0632, a cholecystokininA receptor antagonist, on experimental acute pancreatitis. Jpn J Pharmacol 1997;73:105-112.
266. Niederau C, Grendell JH. Role of cholecystokinin in the development and progression of acute pancreatitis and the potential of therapeutic application of cholecystokinin receptor antagonists. Digestion 1999;60Suppl 1:69-74.
267. Gully D, Frehel D, Marcy C, Spinazze A, Lespy L, Neliat G, Maffrand JP, Le Fur G. Peripheral biological activity of SR 27897: A new potent non-peptide antagonist of CCKA receptors. Eur J Pharmacol 1993;232:13-19.
268. Poncelet M, Arnone M, Heaulme M, Gonalons N, Gueudet C, Santucci V, Thumeyssen O, Keane P, Gully D, Le Fur G, et al. Neurobehavioural effects of SR 27897, a selective cholecystokinin type A (CCK-A) receptor antagonist. Naunyn Schmiedebergs Arch Pharmacol 1993;348:102-107.
269. Le Drean G, Le Huerou-Luron I, Gestin M, Rome V, Bernard C, Chayvialle JA, Fourmy D, Guilloteau P. Pancreatic secretory response to feeding in the calf: CCK-A receptors, but not CCK-B/gastrin receptors are involved. Can J Physiol Pharmacol 2000;78:813-819.
270. González AA, Farre R, Mones J, Capella G, Clave P. Pharmacological and molecular characterization of muscular cholecystokinin receptors in the human lower oesophageal sphincter. Neurogastroenterol Motil 2000;12:539-546.
271. Bunting MW, Beart PM, Widdop RE. Effects of the CCK(A) receptor antagonists SR 27897B and PD140548 on baroreflex function in conscious rats. Eur J Pharmacol 1997;337:35-39.
272. Matto V, Harro J, Allikmets L. The effects of cholecystokinin A and B receptor antagonists on exploratory behaviour in the elevated zero-maze in rat. Neuropharmacology 1997;36:389-396.
273. Kreiss C, Schwizer W, Borovicka J, Jansen JB, Bouloux C, Pignol R, Bischof Delaloye A, Fried M. Effect of lintitript, a new CCK-A receptor antagonist, on gastric emptying of a solid-liquid meal in humans. Regul Pept 1998;74:143-149.
274. 1 receptor for antagonist SR 27897 and agonist SR 146131 binding. Eur J Pharmacol 1999; 383:339-346.
275. Gigoux V, Maigret B, Escrieut C, Silvente-Poirot S, Bouisson M, Fehrentz JA, Moroder L, Gully D, Martinez J, Vaysse N, Fourmy AD. Arginine 197 of the cholecystokinin-A receptor binding site interacts with the sulfate of the peptide agonist cholecystokinin. Protein Sci 1999;8:2347-2354.
276. 1 receptor for interactions with SR 146131, SR 27897 and CCK-8S. Eur J Pharmacol 2000;389:115-124.
277. 1 receptor. Eur J Pharmacol 2000;400:185-194.
278. Akiyama T, Tachibana I, Hirohata Y, Shirohara H, Yamamoto M, Otsuki M. Pharmacological profile of TP-680, a new cholecystokininA receptor antagonist. Br J Pharmacol 1996;117:1558-1564.
279. Tachibana I, Kanagawa K, Yamamoto Y, Otsuki M. Pharmacological profile of a new serine derivative cholecystokinin receptor antagonist TP-680 on pancreatic, biliary and gastric function. J Pharmacol Exp Ther 1996;279:1404-1412.
280. Ohtsuka T, Kotaki H, Nakayama N, Itezono Y, Shimma N, Kudoh T, Kuwahara T, Arisawa M, Yokose K, Seto H. Tetronothiodin, a novel cholecystokinin type-B receptor antagonist produced by Streptomyces sp. NR0489. II. Isolation, characterization and biological activities. J Antibiot (Tokyo) 1993;46:11-17.
281. Ohtsuka T, Nakayama N, Itezono Y, Shimma N, Kuwahara T, Yokose K, Seto H. Tetronothiodin, a novel cholecystokinin type-B receptor antagonist produced by Streptomyces sp. NR0489. III. Structural elucidation. J Antibiot (Tokyo) 1993;46:18-24.
282. Daugé V, Sebret A, Beslot F, Matsui T, Roques BP. Behavioral profile of CCK2 receptor-deficient mice. Neuropsychopharmacology 2001;25:690-698.